Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 18/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 8/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.46 |
| ▸ | PTPRC | P08575 | 3/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.38 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14593136 | 0.91 | PTPN1 (0.51) | PTPN1PTPN2PTPN6PTPRCPTPN11 | |
| SCHEMBL14593120 | 0.91 | PTPN1 (0.52) | PTPN1PTPN2PTPN6PTPRCPTPN11 | |
| SCHEMBL14593055 | 0.88 | PTPN1 (0.44) | PTPN1PTPN2PTPN6PTPRCPTPN5 | |
| SCHEMBL14593188 | 0.86 | PTPN1 (0.50) | PTPN1PTPN2PTPN6PTPRCPTPN11 | |
| SCHEMBL5468252 | 0.84 | PTPN1 (0.57) | PTPN1PTPN2PTPN6PTPRC | |
| SCHEMBL5395213 | 0.84 | PTPN1 (0.50) | PTPN1PTPN2PTPN6PTPRCPTPN11 | |
| SCHEMBL5404409 | 0.84 | PTPN1 (0.48) | PTPN1PTPN2PTPN6PTPRCPTPN11 | |
| SCHEMBL5396750 | 0.84 | PTPN1 (0.49) | PTPN1PTPN2PTPN6PTPRCPTPN11 | |
| SCHEMBL14593187 | 0.81 | PTPN1 (0.48) | PTPN1PTPN2PTPN6PTPRCPTPN11 | |
| SCHEMBL14626946 | 0.81 | HCAR2 (0.33) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163932-B2 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA & CO. (CA) | 2007-01-16 | — | — | US | disclosed |
| US-7163932-B2 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA & CO. (CA) | 2007-01-16 | — | — | US | disclosed |
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA LTD. (CA) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | PTPRF, PTPRO, PTP4A1 | PTPN1 16/4885PTPN2 27/4885PTPN6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.